Bcr-Abl
Os inibidores de Bcr-Abl são terapias direcionadas que inibem a proteína de fusão Bcr-Abl, que é formada devido à translocação do cromossomo Filadélfia e é um dos principais fatores da leucemia mieloide crônica (LMC). Essa proteína também influencia a angiogênese, contribuindo para a progressão do tumor. Os inibidores de Bcr-Abl são essenciais no tratamento da LMC e estão sendo explorados por seu potencial em inibir a angiogênese em vários tipos de câncer. Na CymitQuimica, oferecemos inibidores de Bcr-Abl de alta qualidade para apoiar sua pesquisa em biologia do câncer, angiogênese e terapias direcionadas.
Produtos da "Bcr-Abl"
Ordenar por
Olverembatinib
CAS:Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).Fórmula:C29H27F3N6OPureza:100% - 99.29%Cor e Forma:SolidPeso molecular:532.56Ref: TM-T3071
1mg35,00€2mg48,00€5mg70,00€10mg96,00€25mg210,00€50mg338,00€100mg535,00€1mL*10mM (DMSO)82,00€Imatinib Mesylate
CAS:Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,Fórmula:C29H31N7O·CH4SO3Pureza:100% - 99.97%Cor e Forma:White Crystalline PowderPeso molecular:589.71BCR-ABL-IN-1
CAS:BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.Fórmula:C23H21F4N5OPureza:98%Cor e Forma:SolidPeso molecular:459.44AD57
CAS:AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.Fórmula:C22H20F3N7OPureza:98.23%Cor e Forma:SoildPeso molecular:455.44Ref: TM-T22552L
1mg34,00€2mg52,00€5mg116,00€10mg212,00€25mg359,00€50mg512,00€100mg695,00€200mg939,00€1mL*10mM (DMSO)134,00€Ponatinib
CAS:Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFórmula:C29H27F3N6OPureza:98% - 99.60%Cor e Forma:SolidPeso molecular:532.56AG1024
CAS:AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Fórmula:C14H13BrN2OPureza:98% - 99.37%Cor e Forma:SolidPeso molecular:305.17BCR-ABL-IN-8
CAS:BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].Fórmula:C30H33N7O5Pureza:98%Cor e Forma:SolidPeso molecular:571.63Bosutinib hydrate
CAS:Bosutinib hydrate (SKI-606 hydrate) is a kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of leukemia.Fórmula:C26H31Cl2N5O4Pureza:99.87%Cor e Forma:SolidPeso molecular:548.46Dasatinib hydrochloride
CAS:Dasatinib hydrochloride is an oral Src/Bcr-Abl inhibitor with potent antitumor effects, Ki values of 16 pM (Src) and 30 pM (Bcr-Abl).Fórmula:C22H27Cl2N7O2SPureza:99.88% - 99.98%Cor e Forma:SolidPeso molecular:524.47DPH
CAS:DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.Fórmula:C18H13FN4O2Pureza:99.72%Cor e Forma:SolidPeso molecular:336.32GNF-7
CAS:GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Fórmula:C28H24F3N7O2Pureza:97.05% - 99.47%Cor e Forma:SolidPeso molecular:547.53XL228
CAS:XL228 is an inhibitor of multi-targeted tyrosine kinase (IC50s: 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src, and Lyn, respectively).Fórmula:C22H31N9OPureza:99.07%Cor e Forma:SolidPeso molecular:437.54Ref: TM-T17267
1mg56,00€2mg78,00€5mg99,00€10mg149,00€25mg258,00€50mg393,00€100mg582,00€1mL*10mM (DMSO)110,00€Nilotinib monohydrochloride monohydrate
CAS:Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosineFórmula:C28H22F3N7O·HCl·H2OPureza:99.93%Cor e Forma:SolidPeso molecular:583.99KW-2449
CAS:KW-2449 is a multiple-targeted inhibitor, mostly for Flt3, modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.Fórmula:C20H20N4OPureza:98.43% - 99.89%Cor e Forma:SolidPeso molecular:332.4Vodobatinib
CAS:Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.Fórmula:C27H20ClN3O2Pureza:99.06% - 99.55%Cor e Forma:SolidPeso molecular:453.92Ref: TM-T8882
1mg37,00€5mg79,00€10mg116,00€25mg212,00€50mg340,00€100mg528,00€500mg1.275,00€1mL*10mM (DMSO)87,00€Gypsogenin
CAS:Gypsogenin (639-14-5) is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.Fórmula:C30H46O4Pureza:99.73%Cor e Forma:SolidPeso molecular:470.68Ref: TM-T25476
1mg134,00€5mg315,00€10mg469,00€25mg748,00€50mg1.064,00€100mg1.415,00€1mL*10mM (DMSO)349,00€BGG463
CAS:BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.Fórmula:C30H29F3N6O3Pureza:100% - 95.05%Cor e Forma:SolidPeso molecular:578.58Ref: TM-T4618
1mg62,00€2mg87,00€5mg119,00€10mg188,00€25mg350,00€50mg505,00€100mg730,00€1mL*10mM (DMSO)154,00€HG-7-86-01
CAS:HG-7-86-01 is a selective type II tyrosine kinase inhibitor with antiproliferative activity against mutant T315I- Bcr-Abl for chronic myeloid leukemia (CML).Fórmula:C28H21F3N6O2SPureza:99.07%Cor e Forma:SolidPeso molecular:562.57Adaphostin
CAS:Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.Fórmula:C24H27NO4Pureza:97.31%Cor e Forma:SolidPeso molecular:393.48cSRC/BCR-ABL1-IN-1
cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.Fórmula:C24H27ClN6O4Cor e Forma:SolidPeso molecular:498.96
